# A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors

> **NCT00495144** · PHASE1 · COMPLETED · sponsor: **Threshold Pharmaceuticals** · enrollment: 129 (actual)

## Conditions studied

- Tumors
- Hypoxia

## Interventions

- **DRUG:** TH-302

## Key facts

- **NCT ID:** NCT00495144
- **Lead sponsor:** Threshold Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2011-12
- **Final completion:** 2012-06
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2012-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00495144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00495144, "A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00495144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*